Neonatal Fc receptor mAb (lowers Igs) development: 2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis 2023 FDA approved rozanolixizumab (Rystiggo) for MG 2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG INTERESTING? https://t.co/HB1fJet3Bo https://t.co/OBrd2Y3nye

• Johnson & Johnson reports positive topline results for nipocalimab from a Phase…

Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open. https://t.co/hMlKxIDvlb https://t.co/eNEMuH4Tdc

• Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease | RheumNow

Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/GBTh7UGn1O https://t.co/jlwVAbdIIF

• Machine learning identifies fatigue as a key symptom of fibromyalgia reflected …

EGPA: Benralizumab (BEN) or Mepolizumab (MEP) A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA. https://t.co/V0qWQ5nOzc https://t.co/SoOid5HKcV

• EGPA: Benralizumab or Mepolizumab | RheumNow

Behçet’s Syndrome A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches. https://t.co/Yb3R4K9Zwf https://t.co/JAxqZ3FcQz

• Behçet’s Syndrome | RheumNow

FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/Kg7Dqr54dg https://t.co/X25SKggJzN

• Alvotech, Teva End Rough Road for Humira Biosimilar with FDA Approval

When Meningitis Strikes Twice Amanda Moyer, MD, presents her poster at RWCS 2024. https://t.co/hO8VkcqCkb https://t.co/9tfKI7dEs9

• When Meningitis Strikes Twice | RheumNow

CD19 CAR T-Cell Therapy in Autoimmune Disease The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious. https://t.co/D53xeBdgsu https://t.co/dkrJ2CiSTl

• CD19 CAR T-Cell Therapy in Autoimmune Disease | RheumNow

Fever of Unknown Origin: Not Always an Infection Roel Sanchez Baez, MD presents his poster at RWCS 2024. https://t.co/WiDfcNHuNv https://t.co/gTs78QmE2A

• Fever of Unknown Origin: Not Always an Infection | RheumNow

Excess Cardiovascular Risk in Gout A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders. https://t.co/ThDbAkI0VN https://t.co/uYz9Swu6sR

• Excess Cardiovascular Risk in Gout | RheumNow

Can Biomarkers Improve Cardiovascular Risk Assessments in RA? The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis. https://t.co/NTI57kTtAy https://t.co/idf4qTtKcw

• Can Biomarkers Improve Cardiovascular Risk Assessments in RA? | RheumNow

It's a Sore Subject Cindy Chiu, DO, presents her poster at RWCS 2024. https://t.co/Bl7mAL4grR https://t.co/9rLglObu4V

• It's a Sore Subject | RheumNow

Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open. https://t.co/WApFsSzn1W https://t.co/jNv6MClCRk

• Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease | RheumNow